FGFR4 and hepatocellular carcinoma: H3B-6527 (Joshi et al., 2017) is another highly selective covalent FGFR4 inhibitor and is currently undergoing phase 1 study for the treatment of advanced HCC, liver neoplasms, hepatic carcinoma and so on.